5247422026-04-012026-06-305247422026-06-305247422026-04-012026-06-30in-capmkt:OtherExpenses1Member5247422026-04-012026-06-30in-capmkt:ReportableSegments1Member5247422026-04-012026-06-30in-capmkt:ReportableSegments2Member5247422026-04-012026-06-30in-capmkt:ReportableSegments3Member5247422026-04-012026-06-30in-capmkt:ReportableSegments1Member5247422026-04-012026-06-30in-capmkt:ReportableSegments2Member5247422026-04-012026-06-30in-capmkt:ReportableSegments3Member5247422026-04-012026-06-30in-capmkt:ReportableSegments1Member5247422026-06-30in-capmkt:ReportableSegments1Member5247422026-04-012026-06-30in-capmkt:ReportableSegments2Member5247422026-06-30in-capmkt:ReportableSegments2Member5247422026-04-012026-06-30in-capmkt:ReportableSegments3Member5247422026-06-30in-capmkt:ReportableSegments3Member5247422026-04-012026-06-30in-capmkt:ReportableSegments1Member5247422026-06-30in-capmkt:ReportableSegments1Member5247422026-04-012026-06-30in-capmkt:ReportableSegments2Member5247422026-06-30in-capmkt:ReportableSegments2Member5247422026-04-012026-06-30in-capmkt:ReportableSegments3Member5247422026-06-30in-capmkt:ReportableSegments3Member5247422026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524742CAPLIPOINTNOTLISTEDINE475E01026CAPLIN POINT LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-122026-07-29INRCroresQuarterlyFirst quarterGeographical2026-08-1210:45:002026-08-1213:25:00Not applicable2026-04-012026-06-30UnauditedConsolidated6103600000335500000643910000010706000001963600000-58220000054130000018000002162000009755000004186800000225230000002252300000461800000-50000046130000001791000000000-1000001790900000-186000001772300000176910000021800000175050000021800000152000000223.2723.210023.2723.21The above Unaudited Consolidated Financial Results for the quarter ended June 30, 2026, have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on August 12, 2026 and reviewed by the Statutory Auditors. <br /> 2) The Unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> 3) The Group is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results. <br /> 4)The Board of Directors at their meeting held on 14th May, 2026 declared an interim dividend of Rs. 4.00 (Rs. Four Only) per equity share (200 %) for the financial year 2025-26 and was paid to the shareholders on 8th June 2026. The Board of Directors at their meeting held today have recommended a final dividend of Rs. 4/- per equity share (200%) for the financial year 2025-26 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company. <br /> The total dividend for the financial year 2025-26 including the final dividend (subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be Rs. 8/- per equity share (400%) of the face value of Rs. 2 each. <br /> 5) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary. <br /> <br /> Other Expenses975500000Rest of the World4760700000USA1342900000Unallocated33550000064391000006439100000Rest of the World1584000000USA332700000Unallocated33550000022522000002252200000Rest of the World20212100000USA6727500000Unallocated1502390000041963500000041963500000Rest of the World3508000000USA697900000Unallocated04205900000042059000000Exchange difference in translating the financial statements of foreign operations\-18600000-186000000-18600000